Deutsche Bank Ag\ Zymeworks Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$4.82 - $7.7 $169,182 - $270,270	-35,100 Reduced 27.69%	91,659 $486,000
Q1 2022 May 13, 2022	BUY	$6.0 - $16.98 $7,446 - $21,072	1,241 Added 0.99%	126,759 $830,000
Q4 2021 Feb 11, 2022	BUY	$15.19 - $29.33 $484,211 - $934,952	31,877 Added 34.04%	125,518 $2.06 Million
Q2 2021 Aug 11, 2021	SELL	$26.5 - $38.23 $827,409 - $1.19 Million	-31,223 Reduced 25.01%	93,641 $3.25 Million
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $3.15 Million - $6 Million	105,639 Added 549.49%	124,864 $3.94 Million
Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $178,465 - $250,864	4,562 Added 31.11%	19,225 $909,000
Q3 2020 Nov 12, 2020	SELL	$29.21 - $46.58 $339,566 - $541,492	-11,625 Reduced 44.22%	14,663 $682,000
Q2 2020 Aug 13, 2020	BUY	$33.67 - $40.0 $326,060 - $387,360	9,684 Added 58.32%	26,288 $948,000
Q1 2020 May 14, 2020	SELL	$24.28 - $49.8 $425,045 - $871,798	-17,506 Reduced 51.32%	16,604 $589,000
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $847,292 - $1.55 Million	34,110 New	34,110 $1.55 Million
Q3 2019 Nov 14, 2019	SELL	$22.78 - $29.08 $392,431 - $500,961	-17,227 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$15.0 - $22.49 $196,095 - $294,011	-13,073 Reduced 43.15%	17,227 $378,000
Q1 2019 May 15, 2019	BUY	$14.02 - $16.74 $232,732 - $277,884	16,600 Added 121.17%	30,300 $490,000
Q4 2018 Feb 14, 2019	SELL	$10.95 - $15.44 $51,475 - $72,583	-4,701 Reduced 25.55%	13,700 $201,000
Q3 2018 Nov 14, 2018	SELL	$12.21 - $16.61 $280,182 - $381,149	-22,947 Reduced 55.5%	18,401 $288,000
Q2 2018 Aug 14, 2018	BUY	$11.13 - $21.86 $460,203 - $903,867	41,348 New	41,348 $611,000

Others Institutions Holding ZYME

# of Institutions

Shares Held

296K

Call Options Held

Put Options Held

Strategic Wealth Advisors Group, LLC Sacramento, CA

296K
Shares

$3.63 Million
0.08% of portfolio

View Full List

About Zymeworks Inc.

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $756M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

More about ZYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account